retina Flashcards
operculated hole treated if ?
associated with persistent vitreous traction, Vit Hg , superior or large
symtomatic PVD associated with retinal tear
7-18%
if with Vit Hg 75%
asymptomatic flap tear progress to RD in
5%
asymptomatic LD progress to RD in
1%
risk factors of RRD post phaco
male, young, myopia, high AL, PCR, absence of PVD
highst risk in the first year 11x
more risk of RRD than phakic by 1-3 %
risk of RRD in the fellow eye
10%
subclinical RD or asymptomatic RD
subretinal fluid that extend more than 1 DD form the break but not more than 2 DD posterior to the equater
30% risk to progress
RRD after trauma in young pt
12% in immediatly
30% in the first month
50% after 8 months
80% after 24 months
M.C retinal dialysis in inferotemoral or superonasal
vitreous avalsion
macular hole
horseshoe tear (equatorial, post to meridional fold, post margin of vitreous bsae)
often multiple
FFA dose
2-3 ml of 25% or 5ml of 10% sterile solution in anticubital vien
FFA component
fluorescein dye ( 80% bound to the plasma protien)
fundus camera
excitation filter (blue green 460-490 nm)
barrier filter (yellow 520-530 nm)
phases of FFA
choroidal flush 8-12 s from injection
arterial phase 11-18 s from injection
laminar phase 1-3 s later
venous phase 5-10s later
early recirculation 2-4 min
late recirculation 4-5 min
hypoflaurescence
vascular filling defect
blockage effect
drug causing ME
docetaxal
niacin
deforxamine
fingolimoid
prostaglandin F2a
glitazone
Risk factors for RVO
AGE, HTN, DM, dyslipidemia, smoking, glaucoma, hypercoagulable status, hypothyrodism
retinitis pigmentosa
rod cone dystrophy
tirad of : waxyy pallor of ON, bone specule , attenuated BV
pt complaining of paracentral ring scotoma or restricted peripheral VF and nyctalopia
associated with: vitreous cells, CME, PSC, ERM, ON Drusen
exudative RD and vascular hyperpermabilty (coats like) 2-5%
ERG: reduced both A and B wave
B wave prolonged in duration and diminished in amplitude
intraocular FB that cause reaction
Zinc and aluminium cause mild inflammation and becoma incapsulated
if lareg can cause severe inflammation and PVR, ERM, TRD , phthisis bulbi
iron and cupper( more) are very toxic to the eye
chalcosis»_space; kayser fleischer ring, sunflower cataract , greenish discoloration of the iris, greenish particle in the aqueous , brownish to reddish opacities and strand in the vitreous, metalic fleck on the retina.
Sidrosis deposits on neuroepithelial cells, most toxic to the PR and RPE , early reduced A wave, later on reduced both A and B wave (electronegative ERG)
SOAG , mydriasis , stromal staining, cataract
symptoms: nyctalopia, restricted VF, DOV
pigmentary retinopathy and hearing loss DDx
alport syndrome
alstrom syndrome
refsum syndrome
congenital rubella syndrome
mucopolysaccridosis
cockayne syndrome
BDUMP
- bilateral multiple melanocytic lesions in the choroid
- acute PSCC
- ERD
- iris and CB cysts
terson syndrome %
1/3 of subdural or subarachnoid Hg
Sun ILM , Subhyaloid, Vit Hg
resolved spontaneously , may need vitrectomy
choroidal hemangioma Rx
Diffuse: external beam radiation
circumscribed: PDT
if asymptomatic: no treatment
choroidal hemangioma types
circumscribed: sporadic, usually at the macula, cystoid degenration of the outer retina, exudative retinal detachment.
DDX: amelanotic Choroidal melanoma, choroidal osteoma, choroidal mets, choroidal granuloma
Diffuse CH: SWS, tomato kechup , can cause SACG, ERD
A scan : high amplitude initial echo and high amplitude internal echo
B san: choroidal thickening with high internal reflictivity
FFA: early hyperflauorescnece of large choroidal vessels at choroidal phase followed by stainning of lesion or leakage or pooling of cystoid lesion of overlying retina
ICG: early hyperfluorescence , peak at 3-4 min, wash out at late frame leaving only hyperflourescence rim
infrared imaging
electrophysiologic retinal study
EOG: RPE
multifocal ERG: Macula cone-red fumction
pattern ERG: (checkerboard , contrast sensetivity) , P50 ( PR in the macule), N95 (GCL)
VEP: afferent visual system
types of ocular lymphoma
- primary intraocular or vitreoretinal lymphoma (most aggresive)
- primary uveal lymphoma
- primary ocular adnexa lymphoma
- secondary lymphoma
PVRL
25% of PCNSL will have PVRL
60% PF PVRL will have PCNSL
30% presented unilataral , 85% will affect fellow eye
any pt more than 50 presented with new onset bilateral posterior uveitis consider lymphoma
symptoms: decreased vision and floaters
signs: diffuse vitreous cells and flare, deep sub RPE/ subretina yellow white infiltrate +/- vascultits or vascular occlusion
FFA / ICG : hypofluorescence early and late
Dx: vitrectomy for vitreous +/- subretinal sample for flow cytometry, cytopathology , gene rearrangment study , PCR, IL10: IL6 >1 , MYD88 mutation , Brain imaging and LP
Rx: IV methotrexate +/- IVI methotrexta or rituximab or EB radiotherapy
poor prognosis
characteristic signs suggest PVRL
1-incomplete or partial response to steroid
2-atypical large vitreous cells which is white arranged like string of pearls or sheat like (aurora borealis effect)
3- subretinal/ sunRPE white lesion that is may be transient od shift the location with time
Uveal lypmphoma
more slow pattern
1/3 associated with systemic lymphoma
bridshot uveitis like retinopathy +/- ERD
thickening of uvea on B san
episcleral involvment» salmon patch
AREDS2 supplements
Vit C 500mg, Vit E 400IU, Lutien 10mg, Zeaxanthin 2mg, zinc 80mg, cupper 2mg
DEC porgression up to 25%, Dec moderate Vision loss (>3 lines) up to 19% in 5 years
foradvanced AMD in one eye: subfoveal GA or CNVM
forintermediate AMD:
* extensive intermediate drusen
* single large drusen
* nonfoveal GA
focal VMT
50% sponntaneously released
refsume disease
AR
elevated plasma phytanic acid
pigmentary retinopathy+ cerebellar ataxia+ hearing loss + icthyosis
nyctalopia early sign of the disease
restricted diatry intake of phytanic acid
HTN retinopathy severity
arteriolar narrowing , AV nikking
scheie classification of HTN retinopathy
0: no retinopathy
1:mild arterial narrowing
2:marked arterial narrowning
3: 2+ retinal Hgs and Exudate
4: 3+ optic nerve swelling
HTN choroidopathy
Young PT + acute increase in BP
ischemia of Choriocapillaris
elsching spot : hyperpigmented lesion surrounded by hypopigmented rim (late)
seigrist streaks: hyperpigmentation along choroidal vessels
FFA: early hypoF , multiple subretinal retinal leakage late +/- PED
SRD bilateral
toxo in pregnancy
for 4-6 weeks
spiramycin 400mg TID
intravitreal clindamycin + periocular short acting steroid
azithromycin / clindamycin /atovaquone
sulfonamide can be safely used in the first 2 trimester
finding in congenital toxo
bilateral macular chorioretinal scar
DX of toxoplasmosis
IgM» indicate aquired disease
IgG» if negative rule out the infection
ocular fluid for PCR or goldman whitmer coefficient
quadrable therapy
- sulfadiazine
- pyrimethamine
- prednisolone
- clindamycin
- +folate (to prevent the anemia)
fundus albipunctatus gene
RDH5 in RPE
coding for cis retinol dehydrogenase
CMV retinitis
- CMV MC infectious congenital syndrome
- CMV MC oppurtenistic infection in immunosuppressed pt
- manifested as DOC and flaoters
- area of opacitfied necrotic retin along the vessels with Hgs and CWS or frosted branch angiitis
- usually if the CD4< 50 cells/ul
- treated with oral valgancyclovir (induction 900mg BID for 2-3 weeks then maintainance 900mg once daily until the CD4 > 200 cells/ul) OR
*systemic gancyclovir (5mg/kg BID for 2 weeks or foscarnet 90mg/kg BID for 2 weeks)
+/- IVI gancyclovir** (2mg /0.1 ml)** or foscarnet (1.2-2.4 mg/0.1 ml) - complication 20% recovery inflammation leading to CME , ERM
- 50% can lead to RRD
MC cause of ARN or PORN
VZV» HSV
ARN in both
PORN in immunocompromised Pt (more rapidly progressive)
syphilis work up and PCR for ( VZV,HSV,CMV,TOXO)
treatment systemic +/- IVI (foscarnet or gancyclovir)
1. acyclovir 10mg/kg TID for 10-14 days IV then oral 800mg 5X/day
2. oral valacyclovir 2g TID for 2-3 weels then 1g TID
3. prednisolone (optional) 0.5 mg/kg/day for 3-6 weeks
ERM
- avascular ,transparent, fibrocellular membrane adhere to ILM , result from proliferation of Glial cells (astrocyte and muller) , RPE and hyalocytes
- 20% above the age of 75y
- 10-20% bilateral
- PVD is a requisite for ERM development